Apremilast Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 10 mg, 20 mg, 30 mg

Reference Brands: Otezla(USA)

Category: Immune Disorder

Apremilast is available in Tablets and strengths such as 10 mg, 20 mg, 30 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Apremilast is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Apremilast can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Apremilast, marketed under the brand name Otezla, is an FDA-approved small-molecule phosphodiesterase 4 (PDE4) inhibitor used for the treatment of several immune-mediated conditions. It is indicated for adults with moderately to severely active psoriatic arthritis, plaque psoriasis who are candidates for phototherapy or systemic therapy, and Behçet’s disease associated with oral ulcers. By inhibiting PDE4, apremilast increases intracellular cyclic adenosine monophosphate (cAMP) levels, which helps modulate inflammatory pathways and reduce the production of pro-inflammatory cytokines such as TNF-α, IL-17, and IL-23, thereby decreasing inflammation and immune-mediated tissue damage.

Apremilast is administered orally as a convenient tablet formulation and is generally well-tolerated. Common side effects include gastrointestinal symptoms, headache, and weight loss, while rare but serious adverse events may occur, requiring careful patient monitoring. In addition to its approved indications, apremilast is sometimes used off-label for dermatologic disorders unresponsive to conventional therapies such as systemic corticosteroids or immunosuppressive agents. Its mechanism of action and safety profile make it a valuable option for interprofessional management of patients with moderate to severe psoriatic arthritis, plaque psoriasis, and Behçet’s disease.